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Abstract  
 
Scaling factor values for the in vitro-in vivo extrapolation of hepatic metabolic clearance for 
xenobiotics have not yet been determined in horses. Scaling factors were determined by 
comparing the total protein and or CYP P450 content in microsomes and cryopreserved 
hepatocytes against the content in the liver. Microsomal protein per gram of liver (MPPGL) 
and hepatocellularity number per gram of liver (HPGL) using CYP P450 content method 
ranged 41 - 73 mg/gram of liver (mean= 57 mg/gram of liver, n=39) and 146 - 320 × 106 cells/g 
of liver (mean = 227× 106 cells/g of liver, n=18), respectively; and 156 - 352 × 106 cells/g of 
liver (mean = 232× 106 cells/g of liver) using total protein method. A non-monotonic and 
inverse relationship between age and MPPGL and HPGL, respectively, was observed.  
Between 1 and 20 years of age the liver cell size decreases as age increases. Subsequently, the 
cell size increases until the hepatocytes of the oldest horses approached the size found in the 
youngest horses. Hepatocyte density was inversely related to the size of the hepatocytes. This 
study provides the first extensive and comprehensive data demonstrating the relationship 
between the size of hepatocytes and HPGL in any species. 
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Introduction 
 
Hepatocytes and liver microsomes obtained from several species including human are routinely 
used to determine the intrinsic clearance (Clint) of xenobiotics in the discovery phase of drug 
development (Smith et al. 2008). The generated in vitro Clint values are often extrapolated to 
in vivo using scaling factors such as the hepatocellularity number per gram of liver (HPGL) 
and the hepatic microsomal protein per gram of liver (MPPGL) (Hakooz et al. 2006). A 
relatively good correlation has been established between predicted and actual in vivo clearance 
in human and pre-clinical species (Riley et al. 2005). However, an important animal species 
that has been overlooked regarding in vitro-in vivo extrapolation (IVIVE) of drug clearance is 
the horse. Horses have both a commercial and a domestic role within society, ranging from 
companion animals to the equine sports and food industries. In all cases, the welfare of the 
horses must be considered, including appropriate medication when necessary. Furthermore, the 
equine sports industry which includes young, medium and older horses in flat racing, hurdles 
and Equestrian, respectively, is a multi-billion-dollar global business. Equine sports in addition 
to the food industry, require that any medications administered are at negligible concentrations 
at the time of competition or slaughter, respectively. The drug withdrawal time for negligible 
levels as well as the most appropriate dosing regimen will be dependent on the horse 
pharmacokinetics and therefore the ability to estimate drug clearance is paramount.    
Microsomal scaling factors and hepatocellularity numbers for human, dog, rabbit, rat and 
mouse have been estimated using  methodologies such as DNA, CYP and protein content 
(Carlile et al. 1997; Sohlenius-Sternbeck, 2006; Smith et al. 2008). However, horse MPPGL 
and HPGL have not been investigated. 
The IVIVE of hepatic metabolic drug clearance has been mainly based on mean MPPGL and 
HPGL values for a given species with no estimate of intersubjective variability (Barter at al. 
2007). Furthermore, a recent study found that there was up to 19-fold individual variation in 
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values of MPPGL in 128 human livers (Zhang et al., 2015).  In this context, many reports have 
demonstrated specific age-dependent changes in some hepatic parameters, such as decreased 
protein and bile salt synthesis, and cholesterol metabolism (Tietz et al. 1992; Bertolotti et al. 
1993; Schmucker 2005). Moreover, a number of studies have found strong negative 
correlations between age and hepatic microsomal Phase I drug-metabolising activity in inbred 
male rats (Schmucker & Wang 1980; Schmucker & Wang 1981; Schmucker & Wang 1983; 
Yun et al. 2010). However, the results of studies conducted on non-human primates contradict 
the findings in rat as there was no apparent correlation between age-related changes in the 
microsomes and the in vitro activities of the constituent drug-metabolizing enzymes. (Maloney 
et al. 1986; Schmucker & Wang 1987).  
Several morphological studies have been conducted to study the effect of aging on liver 
structure (Tauchi 1961; Tauchi & Sato 1962; de al Iglesia et al. 1976; Watanabe & Tanaka 
1982). The liver cell density of the inbred rat strain Fisher 344 increased between 1 and 16 
month of age and, subsequently, declined such that the size of cells in immature and senescent 
animals was equivalent (Schmucker et al. 1978). Other changes in hepatocellular structure have 
been associated with advanced age, which include reduction in the surface area of the smooth 
surfaced endoplasmic reticulum, an increase in the volume of the mitochondrial and microbody 
compartments and an increase in hepatocyte polyploidy.  Although none of these age-related 
changes manifest in a significant decline in hepatic function, there are data showing specific 
age related changes, such as a loss of liver size and a drop in liver perfusion (Schmucker et al. 
1977; Schmucker et al., 1978; Watanabe & Tanaka, 1982); both of which may affect certain 
hepatic functions, including first pass pharmacokinetics (Marchesini et al. 1988; Wynne et al. 
1989). 
In order to predict extreme effects in populations and to evaluate risk in horses with different 
age groups such variability should be assessed. Accordingly, the main aim of this study was to 
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determine levels of MPPGL and HPGL as well as the effect of age on these levels and histology 
morphology in equine liver.   
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Materials and Methods 
Chemicals. Hank’s buffered salt solution (HBSS) 10×, without calcium, magnesium or phenol 
red, Collagenase type IV and William’s E Medium, no phenol red were purchased from Fisher 
Scientific (Loughborough, UK), Sodium dithionite (Sigma, UK). All other chemicals and 
reagents were commercial products of analytical grade.  
Source of liver samples.  
Liver samples were collected post slaughter from 39 horses (1-29 years old, the corresponding 
sex of the donor horses was not available) (Supplementary Table S1), slaughtered in 
accordance with the Welfare of Animals at the Time of Killing (UK) Regulations 2015. For 
microsome preparation, liver samples were flash frozen using dry ice. For hepatocyte 
preparation, liver samples were excised by a single transverse cut, and immediately after 
excising, immersed in HBSS (0-2˚C) prior to being transported to the laboratory.  
 
Histological study. Tissue fragments, obtained from 9 horses aged 1, 3, 5, 10, 16, 19, 21, 23 
and 29 years-old, were fixed in 10% formalin for 24 hours at 4 ˚C. After fixation, samples were 
processed using routine methods and embedded in paraffin wax. Sections were cut at 5 µm 
thickness and stained with haematoxylin eosin (H&E). To avoid any biased interpretation each 
slide was assigned a random number and the investigator was blinded to the identity of the 
sample. Three non-overlapping slides per horse were photographed in triplicate using 400x 
magnification (DM5000B, Leica, Germany). The number and size of hepatocytes in a chosen 
area were counted and measured using Image-Pro® plus Software, Media Cypernetics, USA. 
For hepatocyte size, the area of 35 cells/image were measured. The mean±SD was calculated 
using Microsoft Excel (Microsoft Excel 2010, Microsoft Corporation, USA). 
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Homogenization of liver samples. Tissue samples (approximately 5 g), previously stored at -
80˚ C, were thawed on ice and weighed accurately. The samples were finally chopped and 
homogenized using a blender for 60s in 0.15 M potassium chloride buffer pH 7.4 (10 ml/gram 
of liver). To discard any connective tissue, the homogenised samples were filtered through a 
nylon mesh (pore size 250 µm) (Fisher scientific, Loughborough, UK).  
Preparation of microsomes. Microsomes were prepared according to a protocol described by 
Wilson et al. (2003). Briefly, the homogenates were centrifuged at 10,000g for 20 minutes at 
approximately 4˚ C and the supernatant (S24 fraction) retained. The supernatant was then 
centrifuged at 100,000g for 60 minutes and the resulting supernatant was discarded and the 
pellet re-suspended in ice cold 0.1 M phosphate buffered saline (PBS), before being centrifuged 
at 100,000g for a further 60 minutes. The final pellet was then re-suspended in a volume of 
PBS equivalent to two thirds the weight of the original tissue. Samples of all fractions were 
stored at - 80 ˚C pending CYP450 and total protein determination. 
Hepatocyte preparation. Hepatocytes were isolated by a two-step collagenase perfusion as 
described by Bakala et al. (2003). In brief, the liver was perfused at 37˚ C with a calcium-free 
HBSS (pH 7.2) containing 0.1 mM EGTA, followed by perfusion with HBSS containing 
collagenase type IV (1 mg/ml). After their release from the liver, hepatocytes were suspended 
in buffer containing Bovine Serum Albumin, filtered, washed twice by centrifugation, and re-
suspended in Williams E medium. The total number of cells (viable and nonviable cells) in 
each suspension were counted using the Trypan blue exclusion method (Tennant, 1964). 
Homogenization of hepatocyte suspensions. Fresh hepatocyte suspensions of known cell 
concentration were cryopreserved as previously described (Shibany et al. 2016). Cryopreserved 
hepatocytes were thawed and the total number of cells was recounted. Suspensions were 
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homogenized by freezing/thawing cycles. Homogenates were then assayed for CYP P450 
content. 
Protein determination. The total concentration of the protein of homogenate, microsomal 
samples and hepatocyte homogenates  were measured according to Bradford (1976).  
CYP P450 determination. A dithionite difference spectroscopy method (Matsubara et al. 
1976) was used to determine the P450 content of the microsomes, hepatocytes and homogenate 
fractions using a UV4 UV/VIS spectrophotometer (Unicam, Cambridge, UK). 
Values of MPPGL were calculated using the following equation: MPPGL = (nmol CYP 
P450homogenate/g of liver) / (nmol CYP P450microsomal/mg microsomal protein). 
Correction for loss of microsomal protein. The fraction of microsomal protein lost during 
the microsomal preparation process was determined. Since microsomes contain over 96% of 
the CYP P450 content of the liver, the total CYP P450 contents of homogenate and microsomal 
samples were measured and used to determine the correction factors (Wilson et al., 2003). 
Determination of Hepatocellularity.  
CYP P450 content method: The CYP P450 content of whole liver homogenates and 
homogenates of hepatocyte suspensions from 18 equine livers were determined by dithionite 
difference spectrometry. The following equation was then used to calculate HPGL values: 
Number of hepatocytes per gram of liver = (nmol CYP P450homogenate/g of liver) / (nmol CYP 
P450hepatocytes/10
6 cells) (Wilson et al. 2003).  
Protein method: 97% of liver protein is contained in hepatocytes, and in a suspension of 
isolated hepatocytes this value is 99% (Worboys et al., 1996). Hence the hepatocellularity can 
be calculated from the ratio between the liver protein concentration and the protein 
concentration in the corresponding hepatocyte suspension, corrected by 0.97/0.99.  
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Statistical analysis 
All data are presented as means ± standard deviations of the number of samples used. 
Significant differences between groups were determined using an analysis of variance 
(ANOVA) followed by the Tukey multiple range test (P < 0.05). Significance of any linear 
correlations was analysed using the regression slope statistics. All statistics were carried out 
using GraphPad Prism version 6.0 (GraphPad Software Inc., San Diego, CA, USA).  
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Results 
For the 39 livers investigated, the total protein concentration of the liver homogenates and 
microsomes was 21.5±5 mg/ml and 31.1±6 mg/ml, respectively. The mean value for protein 
concentration for the isolated hepatocytes was 1.0±0.3 mg/106 cells. The CYP P450 
concentrations in liver homogenate, equine microsomes and hepatocytes were 29.6±6.6, 
0.510±0.09 and 0.130±0.02 nmol P450/g liver, respectively (Supplementary Table S2). The 
CYP P450 content of whole homogenate correlated with that of microsomes (r2=0.533, p< 
0.0001) Supplementary Figure S1. The ratio of the whole homogenate CYP P450 content to 
the CYP P450 content for microsomes and hepatocytes provided scaling factors for each liver 
with an average of 57 mg microsomal protein/g liver (CV=15%) and hepatocellularity of 227 
x 106 cells/g of liver (CV=26%), respectively (Table 1). For the protein method, the mean 
hepatocellularity was 232×106 cells/ g liver (CV=21%).  The operator had no significant 
influence on estimated values for MPPGL and HPGL as no correlation existed between 
measurements and time for a 21-month period (p > 0.05) Supplementary Figure S2.  
Levels of hepatic total CYP P450 content per gram of liver increased significantly in the horses 
aged between 10 and 20-years-old relative to the <10 and >20-year-old horses (Figure 1A). On 
the other hand, the total CYP P450 content in equine liver microsomes per mg protein did not 
change significantly over the ages examined in this study (Figure 1B).  
A U-shaped relationship was observed between CYP P450 content per 106 hepatocytes and the 
horse age (Figure 1C). Furthermore, Figure 2A shows a non-monotonic relationship between 
age and MPPGL with values increasing from 41 mg/g of liver (5-year-old) to a maximum of 
73 mg/g of liver (17-year-old) followed by a gradual decrease in older age. This gradual 
decrease was not statistically significant, however, the increase in MPPGL in horses aged 10-
20 years old compared to 0-9 years old was significant. Hepatocellularity increased gradually 
with age to reach the maximum level at 19 years old. Subsequently, the cell number declined 
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until the hepatocytes of the oldest horses almost approached the number of those found in the 
youngest horses (Figure 2B). HPGL was significantly higher in horses between 10 and 20-
years-old compared to that in horses <10 and >20 years-old. 
Hepatocellularity determined using the protein method showed a similar pattern to the results 
obtained from the CYP P450 method (Supplementary Figure S3).  
There was an inverse relationship between HPGL and CYP P450 content per 106 hepatocytes, 
i.e. the lower the HPGL the higher the CYP P450 content per 106 cells (Figure 3). 
Age-related alterations in the size and number of equine hepatocytes were studied in 
histological sections of liver samples obtained from 9 horses. The cell size and number per unit 
area (mean± SD) of hepatocytes for each age category is summarised in Table 2. Between 1 
and 20 years of age the cell size of equine hepatocytes decreased in size as age increased. 
Subsequently, the cell size increased until the hepatocytes of the oldest horses approached the 
size of those found in the youngest animals.  Horses between 10 and 20-years-old contained 
significantly smaller hepatocytes than horses older than 21-years-old (Figure 4A). The number 
of hepatocytes per unit area increased and decreased inversely with the changes in hepatocyte 
size over age. There was a significant difference in the number of cells per unit area between 
10 and 20 years and <10 and >20-year-old horses (Figure 4B).  
The HPGL was highly correlated with the number of cells per unit area (r2 = 0.8294, P<0.05) 
and cell size (r2 = 0.7323, P<0.05) shown in Figures 5A and 5B, respectively. 
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Discussion 
Microsomal protein per gram of liver (MPPGL) and hepatocellularity (HPGL) are used 
frequently as scaling factors to predict the in vivo hepatic metabolic clearance of a xenobiotic 
for human (Houston, 1994). However, there is no information about these scaling factors for 
horses reported in the literature. In the present study, the MPPGL and HPGL for horse were 
determined from CYP P450 and protein measurements. 
The CYP P450 content in equine liver microsomes was almost double compared to human; in 
contrast, there was no difference in CYP P450 content in hepatocytes, between horse and 
human (Supplementary Table S2).  The mean value for horse microsomal protein was 57 (41-
73) mg/g of liver, and there was no difference in HPGL between the two methods used; CYP 
P450 content method 227 (146-320) × 106 cells/g of liver and protein method 232 (156-352) × 
106 cells/g of liver. The hepatocellularity number obtained for the horse is higher than other 
species. One possible explanation for this may be due to the diameter of horse hepatocytes 
(14.6±4.8 µm) being smaller than the diameter of hepatocytes from other species; 19.2±0.6 µm 
in rat, 18.4±0.8 µm in pigs, and between 20-30 µm in human (Engelmann et al. 1981; 
Stegemann et al. 2000; Boyer et al., 2017).  On the other hand, the microsomal protein value 
obtained from the horse was similar to values obtained for dog and rat; however, it was higher 
than that obtained for human (Table 1). Furthermore, there is a statistically significant non-
monotonic relationship between age and both MPPGL and HPGL in horses.  
These findings are consistent with the literature for other species; Basu et al. (1971) studied the 
effect of the activity of microsomal drug metabolising enzymes with age in rat liver and found 
that the total microsomal protein increased progressively until the age of 70 days and thereafter 
it remained more or less constant. Moreover, a study which collated and analysed data from a 
number of sources found that there was a weak but statistically significant inverse relationship 
between age and both MPPGL and HPGL in human (Barter et al. 2007). Similarly, Barter et 
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al. (2008) found that values of MPPGL were approximately 36 and 31% lower in new born and 
elderly (80 years old) individuals than those in a 25-year-old individual. However, recently 
Zhang et al. (2015), suggested that the variation in content and activity of human liver 
microsomal protein was due to individual variations rather than an age-dependent variation.  
The micrometric measurements of hepatocytes in histological specimens, in the present study, 
revealed that very young and aged horses possess fewer but larger hepatocytes than middle age 
horses. Moreover, there is an inverse relationship between size and number of hepatocytes in 
a unit area. These findings are in agreement with those reported in the literature; Tauchi (1961) 
reported that the number of cells in human and rat liver samples decreased to a certain degree 
with advanced age while hepatocyte size increased. Furthermore, the fall in hepatocyte number 
with advancing age has been observed in human liver (Wakabayashi et al. 2002).  
The increase in hepatocyte size in young subjects may be due to the fast growth demands in 
this period of age which allows the liver to adapt with a high-energy demand (De la Iglesia et 
al. 1976). On the other hand, the increase in hepatocyte size in aged subjects may be due to 
nuclear polyploidisation rather than compensatory hypertrophy (Tauch & Sato 1962; Watanabe 
& Tanaka 1982).  
While it has been shown that there is a statistically significant inverse relationship between age 
and CYP P450 content/mg microsomes in female horses (Nebbia et al., 2004), the present study 
found that age has no effect on CYP P450 content/mg microsomes. However, the effect of sex 
could not be studied in the present study due to lack of information regarding the corresponding 
sex of donor horses. The results of the present study suggest that the increase of MPPGL was 
due to the increase in the total number of hepatocytes per gram of liver rather than an increase 
in the expression of CYP P450 resulting from an increase in smooth endoplasmic reticulum 
(SER) surface area. This cell-size dependent difference in MPPGL content has been reported 
in human hepatocytes (De la Iglesia et al., 1975). This has been confirmed in the herein study 
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by the presence of a significant inverse relationship between CYP P450 per 106 cells and HPGL 
which may help horses with low HPGL to maintain their xenobiotic metabolic capacity by 
having higher levels of CYP P450 per hepatocyte. This observation has also been reported in 
human hepatocytes (Wilson et al., 2003).  
There are a number of limitations to the present study. Firstly, the corresponding sex of the 
donor horses was not available, hence it was not possible to study the effect of gender on the 
CYP P450 content, MPPGL and hepatocellularity number. Secondly, all liver samples used in 
this study were frozen. A number of studies have found that the freezing of liver samples may 
have a negative effect on the stability of CYP P450. Smith et al. (2008) found that the mean rat 
and dog CYP P450 content determined from frozen homogenate was almost half of the P450 
content of fresh homogenate. However, the activity of CYP P450 in homogenate prepared from 
fresh and frozen rat liver tissue was assessed using several known P450 substrates, and the 
results showed that the intrinsic P450 enzyme activity was unaffected by freezing the 
homogenate. Hence, calculation of microsomal scaling factors should not be affected by the 
freezing of liver samples (Smith et al., 2008). 
Furthermore, a study that was conducted to examine the stability of CYP P450 in frozen human 
microsomes found that the concentration of CYP P450 decreased by 20-40% (Pearce et al. 
1996). However, freezing human liver tissue had no effect on the stability of CYP P450 which 
suggests it does not convert to its inactive P420 form, but the accuracy of the P450 assay may 
have been affected due to contamination of liver tissue fractions with haemoglobin and other 
haem-containing proteins (Pearce et al., 1996).  
The values of MPPGL and HPGL determined for horse in the present study can be used to 
scale up the in vitro intrinsic clearance (Clint) of a drug, measured in microsomes or 
hepatocytes, to the liver metabolic intrinsic clearance (Iwatsubo et al., 1997). This scaled value 
can then be used to estimate the hepatic metabolic clearance in horse using models such as the 
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well stirred or parallel tube model. However, this requires a knowledge of hepatic blood flow 
and the plasma free fraction of drug in horse. Furthermore, the scaling factors determined in 
this study can be used in conjunction with data from other species to perform interspecies 
allometric scaling (Mahmood, 2007). In this context, Lave et al. (1996) successfully predicted 
bosentan clearance in human by combining data obtained from in vitro liver systems i.e. 
hepatocytes and microsomes, with the in vivo clearances in animals. Therefore, interspecies 
allometric scaling of animal clearance values, corrected for liver metabolic intrinsic clearance 
estimated using the herein in vitro scaling factors, may improve predictions of hepatic 
metabolic clearance in the horse. Alternatively, interspecies allometric scaling for drug 
clearance, that includes horse, can be corrected for liver metabolic intrinsic clearance obtained 
from human in vitro studies in order to predict human hepatic metabolic clearance. The addition 
of horse as a species would mean that the human prediction results from allometric 
interpolation rather than extrapolation as the horse has a larger body weight. 
In conclusion, this study has established values for equine liver microsomal and hepatocyte 
number scaling factors of 57 mg microsomal protein per gram liver and 227 x 106 per gram 
liver, respectively. This is the first time that these scaling factors have been determined for the 
horse. Furthermore, the influence of age was investigated, and the results suggest that MPPGL 
and HPGL values are dependent on the age of the horse and corrections should be made when 
predictions of hepatic clearance for xenobiotics are carried out using in vitro-in vivo 
extrapolation. 
Finally, further investigation is needed with regard to the effect of horse gender and breed on 
MPPGL and HPGL. 
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TABLE 1 
 
Calculated horse data compared with other species. Source (Sternbeck, 2006; Barter et 
al. 2007; Smith et al. 2008) 
*Hepatocellularity (cells×106/ 
g liver) 
Hepatocellularity (cells×106/ g 
liver) 
Microsomal protein 
(mg protein/ g liver) 
Species 
139±25 99 (74-131) 32 (29-34) Human 
215±45 169 (131-207) 55 (48-62) Dog 
117±30 163 (127-199) 61 (47-75) Rat 
232±49 227 (146-320) 57 (41-73) Horse 
   * hepatocellularity was determined using protein method         
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TABLE 2 
Hepatocyte size and number of cells per unit area at different ages 
 0-9 years 10-20 years >20 years 
 1 3 5 10 18 19 21 23 29 
Cell size (µm2) 171.2 
± 16.9 
188.1 
± 22.3 
163.6 
± 23.7 
162.0 
± 12.4 
146.8 
± 16.3 
137.7 
± 15.0 
172.2 
± 18.5 
175.0 
± 24.4 
196.3 
± 13.7 
No of cells 150.3 
± 5.5 
138.3 
± 6.7 
160 
± 2.0 
171.6 
± 14 
176 
± 13 
201 
± 12 
141.3 
± 2.0 
137 
± 4.0 
133 
± 2.5 
Values expressed as mean ± SD, measurements performed in triplicate for each animal 
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Legends for figures:  
 
Figure 1. Relation between horse age and nmol CYP P450/g of liver (A), nmol P540/mg of 
liver microsomal protein and horse age (B), CYP P450 content per 106 hepatocytes (C) (n=39). 
Comparisons of the three different age groups were made using a one-way ANOVA followed 
by Tukey’s multiple comparison test (F). Each value represents the mean ± SD for 7-16 horses. 
* = P<0.05 
 
Figure 2. Relation between horse age and MPPGL (n=39) (A), HPGL (n=18) (B).  Comparisons 
of the three different age groups were made using a one-way ANOVA followed by Tukey’s 
multiple comparison test (B). * = P<0.05. 
 
Figure 3. Correlation between HPGL and CYP P450 content per 106 cells for 18 equine livers 
(r2 = 0.3926, P<0.05)  
 
Figure 4. Relation between age and size (A) and the number of hepatocytes per unit area (B) 
(n=9). Comparisons of the three-different age groups were made using a one-way ANOVA 
followed by Tukey’s multiple comparison test (B). Each value represents the mean ± SD for 3 
horses. * = P<0.05. 
 
Figure 5.  Relationship between HPGL and number of cells (A) and cell size (B). There is a 
strong (r2 = 0.8294) and (r2 = 0.7323), statistically significant (P<0.05) relationship between 
these values, respectively.  
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